GLP-1 Agonists and WADA: The Sports Status
Peptide Doping and Anti-Doping
Monitored, Not Banned
Semaglutide has been on WADA's Monitoring Program since 2024. As of 2026, GLP-1 agonists remain permitted in all sports. Tirzepatide was added to the monitoring list starting January 2026.
WADA 2026 Monitoring Program
WADA 2026 Monitoring Program
View as imageSemaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not banned in sports. As of January 2026, both drugs sit on WADA's Monitoring Program, a surveillance tool that tracks patterns of use across sports without imposing sanctions[1]. Athletes can currently use GLP-1 agonists without violating anti-doping rules. But this status is provisional. WADA's monitoring of GLP-1 drugs will determine whether they move to the Prohibited List before the 2028 Los Angeles Olympics. Understanding how peptide doping is detected provides essential context for why GLP-1 drugs occupy this unusual regulatory position, where a drug that clearly affects body composition remains legal while growth hormone secretagogues are explicitly banned.
Key Takeaways
- GLP-1 receptor agonists (semaglutide, tirzepatide) are NOT on the WADA Prohibited List as of 2026 and are legal in all sports
- Semaglutide has been on WADA's Monitoring Program since 2024; tirzepatide was added to monitoring in January 2026
- WADA is developing analytical methods for detecting GLP-1 agonists in blood samples through its accredited laboratories
- The STEP 1 trial showed semaglutide 2.4 mg produced 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM, 2021), a magnitude with clear implications for weight-class and power-to-weight ratio sports
- To be banned, a substance must meet at least 2 of 3 WADA criteria: performance enhancement potential, health risk to athletes, and violation of the spirit of sport
- If monitoring data from 2024-2027 shows misuse in sport, GLP-1 agonists could be prohibited before the 2028 LA Olympics
How WADA decides what to ban
WADA uses a three-criteria test to determine whether a substance belongs on the Prohibited List. A substance must meet at least two of three criteria: (1) it has the potential to enhance or enhances sport performance, (2) it represents an actual or potential health risk to the athlete, and (3) it violates the spirit of sport.
For GLP-1 agonists, the analysis is not straightforward.
Performance enhancement: Semaglutide 2.4 mg produces a mean 14.9% body weight loss over 68 weeks[2]. In weight-class sports (boxing, wrestling, judo, weightlifting) and power-to-weight ratio sports (cycling, distance running, triathlon), this magnitude of weight loss confers obvious competitive advantage. An endurance cyclist who loses 15% of body weight without losing proportional power output gains a measurable watts-per-kilogram advantage on every climb. However, semaglutide also causes muscle mass loss alongside fat loss. The STEP 1 trial showed approximately 40% of weight lost was lean mass, not fat. For sports requiring explosive power or raw strength, GLP-1-induced weight loss could be performance-reducing rather than performance-enhancing. The performance effect is sport-specific and dose-dependent.
Health risk: GLP-1 agonists cause gastrointestinal side effects (nausea, vomiting, diarrhea) in 20-40% of users. For athletes training intensely, GI distress during competition could impair performance and cause dehydration. Delayed gastric emptying affects fueling strategies during endurance events. Chronic caloric restriction from appetite suppression during heavy training loads risks relative energy deficiency in sport (RED-S), with consequences for bone health, immune function, and hormonal status. These are real health risks, but they are also risks inherent to the drug's therapeutic use, not unique to athletic misuse.
Spirit of sport: This criterion is the most subjective. Taking a drug to lose weight for a sport where weight matters could be considered analogous to taking a diuretic to make weight, and diuretics have been on the Prohibited List for decades. The counterargument: semaglutide is prescribed to millions of people for medical conditions, and banning a widely used therapeutic drug creates complications for athletes who genuinely need it for diabetes or obesity management.
The monitoring program: what it means and does not mean
The WADA Monitoring Program is not a waiting room for the Prohibited List. It is a data collection mechanism. WADA-accredited laboratories report the presence of monitored substances in athlete samples, allowing WADA to build a picture of prevalence across sports, competition levels, and time periods. Being on the monitoring list means WADA is watching, not that a ban is imminent.
Semaglutide entered the Monitoring Program in 2024. Tirzepatide was added in January 2026. From 2026, markers of both drugs are being tracked in-competition and out-of-competition. The monitoring window for GLP-1 agonists is expected to continue through at least 2027, after which WADA's scientific committees will evaluate the collected data and make a recommendation.
If the data shows significant prevalence of GLP-1 use among athletes in weight-sensitive sports, and if scientific evidence accumulates supporting a performance-enhancing effect, the pathway to prohibition opens. The fastest a ban could take effect would be the 2028 Prohibited List, which would be published in September 2027 and take effect January 1, 2028. This timing would make GLP-1 agonists a banned substance at the 2028 Los Angeles Olympics.
Detection: how laboratories identify GLP-1 agonists
WADA published a technical document in 2024 on the analysis of GLP-1 receptor agonists (semaglutide, liraglutide, and others) in blood samples. The detection relies on liquid chromatography coupled with mass spectrometry (LC-MS/MS), the same analytical platform used for detecting other peptide drugs in doping control[3].
Semaglutide has a half-life of approximately one week, and plasma concentrations remain detectable for several weeks after the last dose. Unlike short-acting peptides that are difficult to catch outside narrow detection windows, the long half-life of modern GLP-1 agonists makes detection relatively straightforward. This is one reason WADA can afford to monitor rather than prohibit: if a future ban occurs, enforcement through existing testing infrastructure is feasible.
The analytical challenge is primarily one of establishing population-level reference ranges and distinguishing therapeutic use (athletes with prescriptions) from misuse (athletes using GLP-1 drugs solely for competitive advantage). Thevis et al. demonstrated as early as 2011 that LC-MS/MS-based methods could reliably detect selected peptide hormones in doping control samples[4], and subsequent advances have made detection of most peptide drugs reliable even at low concentrations.
Which sports are most affected
The performance implications of GLP-1 agonists are not uniform across sports.
High-impact sports (clear weight advantage):
- Cycling: Power-to-weight ratio is the primary determinant of climbing performance. A 10-15% weight reduction with maintained power is transformative. Professional cycling has the culture and history of weight manipulation (from starvation diets to diuretics) that makes GLP-1 adoption plausible.
- Distance running and triathlon: Similar power-to-weight dynamics. Reports of GLP-1 use in recreational triathlon and marathon communities have been widely discussed.
- Weight-class combat sports: Boxing, MMA, judo, wrestling, and weightlifting all involve making weight. GLP-1 agonists offer a method to compete at a lower weight class without the acute dehydration and refeeding cycles that traditional weight cutting involves.
Low-impact sports (minimal or negative effect):
- Strength sports: Loss of lean mass alongside fat mass could reduce absolute strength. A powerlifter or shot putter losing 40% lean tissue from a 15% weight cut would likely perform worse.
- Team sports: Baseball, football, basketball have minimal weight-class dynamics. GLP-1 use would be therapeutically motivated rather than performance-motivated in most cases.
- Precision sports: Archery, shooting, equestrian events have no meaningful weight advantage.
The weight-class loophole problem
In weight-class sports, GLP-1 agonists present a novel challenge because they enable what traditional weight manipulation cannot: sustained body composition change rather than acute water manipulation. A boxer who uses semaglutide for 6 months to drop from middleweight to welterweight is fundamentally different from a boxer who dehydrates overnight to make weight. The GLP-1 user arrives at competition at their actual body weight with normal hydration, while traditional weight cutters compete dehydrated with impaired performance.
This is arguably fairer and safer than traditional weight cutting, which causes acute kidney injury, cognitive impairment, and has contributed to athlete deaths. The paradox: if WADA bans GLP-1 agonists in weight-class sports, athletes may return to more dangerous traditional weight-cutting methods. If WADA allows them, athletes who use GLP-1 drugs gain a structural advantage over those who do not.
Therapeutic Use Exemptions: the likely framework
If GLP-1 agonists move to the Prohibited List, athletes with genuine medical need (type 2 diabetes, obesity with comorbidities) would apply for Therapeutic Use Exemptions (TUEs). The TUE process requires documented medical diagnosis, evidence that the banned substance is necessary (not merely convenient), and demonstration that alternative permitted treatments are inadequate.
For athletes with type 2 diabetes, a TUE for semaglutide would be straightforward to justify. For athletes whose primary indication is weight management without diabetes, TUE approval would be more complex. WADA would need to distinguish between athletes using GLP-1 drugs for legitimate health reasons and athletes using them for competitive advantage in weight-sensitive sports.
This distinction is familiar territory. Testosterone requires a TUE for hypogonadal athletes. Stimulants require TUEs for ADHD. GLP-1 TUE criteria would likely mirror these existing frameworks, with the challenge being that obesity is both a legitimate medical condition and a competitive factor in certain sports.
Comparison with other peptides in sports
GLP-1 agonists occupy an unusual position relative to other peptide-based substances in anti-doping:
| Substance | WADA Status | Reason |
|---|---|---|
| Growth hormone (GH) | Banned | Direct anabolic, performance-enhancing |
| GH secretagogues (GHRP-6, ipamorelin) | Banned | Indirect GH elevation |
| BPC-157 and TB-500 | Banned | Growth factor modulation |
| Insulin | Banned (non-diabetics) | Anabolic, glycogen manipulation |
| EPO (erythropoietin) | Banned | Oxygen-carrying capacity |
| Semaglutide | Monitored | Weight loss, not directly anabolic |
| Tirzepatide | Monitored | Weight loss, not directly anabolic |
The common thread among banned peptides is direct performance enhancement through anabolic, oxygen-carrying, or recovery mechanisms. GLP-1 agonists do not fit this pattern. Their performance-relevant effect (weight loss) is indirect and sport-specific. For a full list of every banned peptide in sports, see our dedicated article.
The detection methods developed for GLP-1 monitoring build on a decade of progress in peptide doping analysis. Judak et al. reviewed how LC-MS-based methods advanced to enable reliable detection of banned peptide substances including growth hormone releasing factors and GnRH analogs[5]. The analytical infrastructure to detect GLP-1 drugs already exists; the policy question is whether to use it for prohibition or just surveillance.
What happens next
The most likely trajectory: WADA continues monitoring through 2027, reviews the data, and makes a sport-specific determination rather than a blanket ban. Weight-class sports may see GLP-1 agonists prohibited while non-weight-class sports may see them remain permitted, similar to how beta-blockers are banned only in sports where steadiness matters (archery, shooting) but not in others.
The alternative: WADA adds GLP-1 agonists to the general Prohibited List with a TUE pathway, similar to insulin. This approach is simpler to administer but creates significant TUE burden for the millions of athletes (recreational and competitive) who use these drugs medically.
Neither outcome is certain. What is certain: GLP-1 agonists are legal in all sports today, and any athlete with a prescription can use them without anti-doping consequences.
The Bottom Line
GLP-1 receptor agonists including semaglutide and tirzepatide are currently permitted in all sports. Both drugs sit on WADA's Monitoring Program, where usage patterns are being tracked through accredited laboratory analysis. The 15% average body weight loss from semaglutide has clear performance implications for weight-class and power-to-weight ratio sports, but GLP-1 drugs do not fit the traditional profile of banned performance-enhancing substances. Whether monitoring data triggers a move to the Prohibited List before the 2028 LA Olympics depends on evidence of misuse and WADA committee deliberations through 2027. How body composition changes on semaglutide directly affects the performance analysis for different sports.